Company intelligence / Profile preview

eVeliko

Cambridge, Massachusetts, United Stateseveliko.com ↗

Ownership: Private
Development stage: Other

Overview

Evelo Biosciences developed orally delivered microbiome-based therapies targeting immune modulation through the small intestine using its SINTAX platform. Lead assets failed to meet efficacy endpoints in mid-stage trials for inflammatory skin diseases, leading to layoffs and eventual company dissolution by late 2023. Earlier efforts included programs in cancer and COVID-19 that were discontinued prior to shutdown. No products reached approval or commercialization.

Therapeutic areas: OncologyDermatologyInfectious Diseases
Modalities: Live biotherapeutic product therapyMicrobial extracellular vesicle therapy
Industry: Biotech

Partnerships

University of Chicago (licensed cancer program)Mayo Clinic (anti-inflammatory drug collaboration)

Beyond the preview

Go deeper on eVeliko.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eVeliko.

Explore the full profile